Apta 1
Alternative Names: Apta-1Latest Information Update: 28 Aug 2024
At a glance
- Originator Aptahem
- Developer Aptahem; University Health Network
- Class Anti-infectives; Anti-inflammatories; Anticoagulants; Antiseptics; Antithrombotics; Oligonucleotides; Peptide aptamers
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Sepsis
Highest Development Phases
- Phase I Sepsis
- No development reported SARS-CoV-2 acute respiratory disease
Most Recent Events
- 28 Aug 2024 No recent reports of development identified for preclinical development in SARS-COV-2 acute respiratory disease in Canada (Parenteral)
- 05 Oct 2023 Safety data from a phase I trial in Sepsis released by Aptahem AB
- 15 Sep 2023 Aptahem AB plans to submit compiled data to the Ethics Committee and Competent Authority after the data review meeting